Hematology

Latest News

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com

Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

By Rose McNulty

July 11th 2025

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

By Kimberly Rath, PharmD

July 7th 2025

Artwork of community health care with a giant stethoscope and medicine bag | Image credit: TarikVision - stock.adobe.com.

Academic-Community Partnerships Bringing Cancer Care to Patients

By Laura Joszt, MA

July 5th 2025

Clinical trial graphic | Image credit: photon_photo - stock.adobe.com

Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

By AJMC Contributor

July 5th 2025

White blood cells | Image credit: Sebastian Kaulitzki - stock.adobe.com

Basophil, Eosinophil Counts Could Be Prognostic Indicators in ET, PV

By Jared Kaltwasser

July 2nd 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

More News

NIH Panel Features Experiences of Young Adults in Rare Disease Community

March 6th 2018

NIH Panel Features Experiences of Young Adults in Rare Disease Community

During a discussion, 4 panelists addressed their main issues of growing up with rare diseases, including that physicians often doubted their feelings of pain and distress.

HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age

February 28th 2018

HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age

Laura Joszt, MA

New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.

February 28th 2018

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD

Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment

February 25th 2018

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment

Blood or marrow transplantation (BMT) can have an impact on a patient’s cognitive functioning, affecting a survivor’s ability to integrate with a group of people and return to work. In addition, BMT recipients can experience a weakened memory, a loss of attention and concentration, and difficulty learning.

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg

CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.

Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma

February 16th 2018

Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma

Laura Joszt, MA

New research published in The Lancet Oncology found that denosumab was noninferior to zoledronic acid for time to skeletal-related events in patients with newly diagnosed multiple myeloma.

February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS

The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.

Study Documents Chronic Pain Associated With Sickle Cell Disease

February 14th 2018

Study Documents Chronic Pain Associated With Sickle Cell Disease

Allison Inserro

Sickle cell disease (SCD), the most common inherited blood disorder in the United States, is marked by episodes of acute pain, but there is increasing recognition that it can transition to chronic persistent SCD pain. A recent study found that the presence of pain on 3 or more days a week is independently associated with worse patient-reported pain interference and anxiety.

Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma

February 14th 2018

Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma

Laura Joszt, MA

The addition of daratumumab to standard-of-care regimens used to treat multiple myeloma, such as bortezomib, melphalan, and prednisone, decreased the risk of disease progression or death in newly diagnosed patients who were ineligible for autologous stem-cell transplantation.

New Imaging Technique Reveals Inner Structure of Red Blood Cells

February 9th 2018

New Imaging Technique Reveals Inner Structure of Red Blood Cells

Allison Inserro

Researchers have used super-resolution microscopy to unveil the geodesic mesh that supports the outer membrane of a red blood cell, in a discovery that could eventually help uncover how the malaria parasite hijacks this mesh when it invades and eventually destroys red blood cells. The work was published in the latest issue of Cell Reports.

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

February 9th 2018

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

Laura Joszt, MA

A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.

February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

CAR T-Cell Therapy Effective for Children With ALL, Updated Study Results Show

February 1st 2018

CAR T-Cell Therapy Effective for Children With ALL, Updated Study Results Show

Allison Inserro

Final updated results of the pivotal phase 2 study that led to last year’s FDA approval of the first chimeric antigen receptor (CAR) T-cell therapy were published Wednesday in the New England Journal of Medicine.

February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.

ICER Report: Despite High Price, Emicizumab for Hemophilia A Cuts Costs

January 31st 2018

ICER Report: Despite High Price, Emicizumab for Hemophilia A Cuts Costs

Jaime Rosenberg

While the wholesale acquisition cost of the hemophilia A drug is approximately $482,000 for the first year of treatment and $448,000 for subsequent years, a draft report found that the drug would reduce the budget by approximately $1.85 billion per patient annually for patients aged 12 and older. In patents aged 12 and younger, emicizumab at wholesale acquisition cost pricing would reduce the budget by approximately $720,000 per patient annually.

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

January 27th 2018

Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer

Laura Joszt, MA

Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.

$Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM$

January 22nd 2018

Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM

Laura Joszt, MA

The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).

Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds

January 20th 2018

Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds

Laura Joszt, MA

Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.

Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations

January 18th 2018

Study Finds Protein Markers May Better Predict Drug Response in Patients With AML Than Genetic Mutations

A study finds that protein markers may be a better predictor of drug response than genetic mutation are in patients with acute myeloid leukemia (AML). As a result, some patients who could benefit from treatment may not be eligible under current approval specifications.

Julie Wolfson: Supporting AYAs Before and After Treatment

January 14th 2018

Julie Wolfson: Supporting AYAs Before and After Treatment

The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

Promacta Earns Breakthrough Therapy Designation by FDA for Severe Aplastic Anemia

January 11th 2018

Promacta Earns Breakthrough Therapy Designation by FDA for Severe Aplastic Anemia

Samantha DiGrande

Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia (SAA).

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

January 7th 2018

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

January 4th 2018

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

Jaime Rosenberg

Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.

Risk Model Predicts Mortality in Patients With AML

December 31st 2017

Risk Model Predicts Mortality in Patients With AML

Allison Inserro

Acute myeloid leukemia (AML) is the most common form of acute leukemia and has a poor 5-year survival rate, especially among older people. Cancer researchers have created a model that can predict mortality after AML treatment, so that it can help guide decision-making for patients and providers.

Determining Discharge Criteria for Pediatric Patients Admitted With Febrile Neutropenia

December 30th 2017

Determining Discharge Criteria for Pediatric Patients Admitted With Febrile Neutropenia

Management of pediatric oncology patients with febrile neutropenia and hospitalization duration currently vary by institution and by provider. A poster presented at the 59th American Society of Hematology Annual Meeting reviewed pediatric hematology/oncology patients who were admitted with febrile neutropenia to determine discharge and release, as well as subsequent readmission within the next 4 days.

Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma

December 29th 2017

Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma

The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

...

19 20 21 22 23 24 25 26 27 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions